Results 91 to 100 of about 4,657 (129)

Real-world safety and implementation challenges of lecanemab therapy for Alzheimer's disease in South Korea: a single-center experience. [PDF]

Alzheimers Res Ther
Jang H, Kim JW, Hwang JW, Jeong DW, Ka J, Kang DM, Suh CH, Choi Y, Oh M, Kim JS, Lim JS, Lee JH.   +11 more
europepmc   +1 more source

Attitudes of specialist memory-clinic patients with early symptomatic Alzheimer's disease towards lecanemab: results from a multicenter survey in Europe. [PDF]

Sci Rep
Vöglein J, Levin J, Stögmann E, Haass C, Höglinger GU, Frölich L, Jessen F.   +6 more
europepmc   +1 more source

Lecanemab use in Chinese patients with Alzheimer's disease: a 12-month multicenter real-world study. [PDF]

Alzheimers Dement
Wu H, Chen Q, Fang M, Tang H, Liu H, Liu J, Zhang J, Chi L, Liu S, Xin J, Leng L, Wang P, Chi S, Li Y, Chen J, Zhang L, Zhang J, Ma Q, Wang X, Meng X, Nao J, Li X, Lv Y, Jia Y, Zhao Q, Liu C, Gan J, Zhu J, Song Y, Li H, Fei M, Guo X, Liu J, Peng G, Chen X, Ji Y.   +35 more
europepmc   +1 more source

National Monthly Outpatient Claim-Recorded Lecanemab Drug Amount in Japan During Fiscal Year 2024. [PDF]

Geriatr Gerontol Int
Omura T, Kamihara T.
europepmc   +1 more source

Clinical Practice Outcomes With Lecanemab for Alzheimer Disease. [PDF]

Neurol Open Access
Liu AJ, Moghadam AA, Alam MS, Lutz MW, Navarra A, Luo S, Wang LA, Petrella JR, Whitson H, O'Brien RJ, Johnson KG, Parker D, Beam C, Sanfilippo M, Al-Sahlani H, Cobb S, Liu MY, Doraiswamy PM.   +17 more
europepmc   +1 more source

Comparison of safety of lecanemab and donanemab: a real-world disproportionality analysis using the FDA adverse event reporting system. [PDF]

Front Pharmacol
Feng X, Bi S, Shi C, Chang Q, Zhang J, Zhuang Y.   +5 more
europepmc   +1 more source

Characterization of the Anti-Alzheimer Drug Lecanemab by Mass Spectrometry. [PDF]

ACS Omega
Sha J, Geng Z, Qi S, Du L, Hu Q, Cai M, Chen D, Chen Y, Liu S, Song H, Ling T, Chang C, Bai B.   +12 more
europepmc   +1 more source

Real-world implementation of lecanemab in Korean patients at a tertiary memory clinic: Safety, ARIA risk, and early treatment patterns. [PDF]

Alzheimers Dement (Amst)
Shin J, Suh SI, Park YJ, Lee S, Kang J, Lee ES, Jung HN, Ryoo I, Lee S, Eo JS, Oh K, Koh SB, Kang SH.   +12 more
europepmc   +1 more source